沙库巴曲缬沙坦在合并心力衰竭透析患者中的应用

doi:10.3760/cma.j.issn.1007-1245.2023.18.002

摘要/Abstract

摘要：

沙库巴曲缬沙坦作为一种具有抑制血管紧张素受体脑啡肽分解作用的药物，能够有效地阻断血管紧张素受体并抑制利钠肽分解，进而降低肾素-血管紧张素-醛固酮系统的激活水平。同时，能促进心肌结构的重构，抑制心肌纤维化的发生，还能显著提高肾小球滤过率，延缓肾功能的恶化。沙库巴曲缬沙坦的药物成分能够有效地降低患者的心血管风险，同时延缓慢性肾脏病的进展，从而对患者的身体健康产生积极的影响。因此，沙库巴曲缬沙坦是应用于心力衰竭、高血压及尿毒症等疾病的重要药物之一，但长期使用也可能会引起一些不良反应，特别是肾脏损害。目前，对于沙库巴曲缬沙坦应用于终末期肾病合并心力衰竭患者中的报道较少，本综述旨在探究其在维持性透析合并心力衰竭患者中的应用情况，并对其安全性进行评估，以期为相关领域的研究提供参考。

关键词:

心力衰竭, 透析, 沙库巴曲缬沙坦, 终末期肾病, 进展

Abstract:

Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor. It can inhibit the breakdown of endogenous natriuretic peptides and block angiotensin receptors, thereby reducing the activation of the renin-angiotensin-aldosterone system. It can also promote myocardial remodeling, inhibit myocardial fibrosis, increase the glomerular filtration rate, and delay the deterioration of renal function. Sacubitril/valsartan is beneficial to patients with chronic kidney disease by reducing cardiovascular risk and delaying the progression of chronic kidney disease. As a result, sacubitril/valsartan is one of the important drugs for heart failure, hypertension, and uremia. However, its long-term use may also cause some adverse reactions, especially kidney damage. There are few reports on the application of sacubitril/valsartan in patients with end-stage of renal disease and heart failure. The purpose of this study is to observe the application of sacubitril/valsartan in maintenance dialysis patients with heart failure, to investigate its safety, and to provide references for researches in relevant fields.

Key words:

Heart failure, Dialysis, Sacubitril/valsartan, End-stage renal disease, Progress

席哲帆杨佳邹皓珍董华.

沙库巴曲缬沙坦在合并心力衰竭透析患者中的应用 [J]. 国际医药卫生导报, 2023, 29(18): 2522-2525.

Xi Zhefan, Yang Jia, Zou Haozhen, Dong Hua.

Application of sacubitril/valsartan in patients with heart failure taking dialysis [J]. International Medicine and Health Guidance News, 2023, 29(18): 2522-2525.

参考文献

[1] Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)[J]. J Clin Pharmacol, 2010,50(4):401-414. DOI: 10.1177/0091270009343932.
[2] Khder Y, Shi V, McMurray JJV, et al. Sacubitril/Valsartan (LCZ696) in heart failure[J]. Handb Exp Pharmacol, 2017,243:133-165. DOI: 10.1007/164_2016_77.
[3] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021,42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368.
[4] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.DOI:10.3760/cma.j.issn.0253- 3758. 2018.10.004.
[5] De Vecchis R, Ariano C, Soreca S. Antihypertensive effect of sacubitril/valsartan: a meta-analysis[J]. Minerva Cardioangiol, 2019,67(3):214-222. DOI: 10.23736/S0026-4725.19.04869-2.
[6] Bayard G, Da Costa A, Pierrard R, et al. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation[J]. Int J Cardiol Heart Vasc, 2019,25:100418. DOI: 10.1016/j.ijcha.2019.100418.
[7] 鄢佳妮. 慢性肾脏病5期患者发生主要心血管不良事件的危险因素及预后分析[D].重庆医科大学,2022.DOI:10.27674/d.cnki.gcyku.2021.001088.
[8] Wang F, Yang C, Long J, et al. Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET) [J]. Kidney Int, 2019,95(3):501-505. DOI: 10.1016/j.kint.2018.11.011.
[9] 程慧栋.腹膜透析患者心血管并发症及其防治[J].肾脏病与透析肾移植杂志,2016,25(5):479-483.DOI:10.3969/cndt.j.issn.1006-298X.2016.05.017.
[10] Fu EL, Evans M, Carrero JJ, et al. Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study[J]. BMJ, 2021,375:e066306. DOI: 10.1136/bmj-2021-066306.
[11] Hou F, Jiang J, Chen J, et al. China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis[J]. BMC Nephrol, 2012,13:94. DOI: 10.1186/1471-2369-13-94.
[12] 吕文律,丁小强,滕杰,等.血液透析和腹膜透析患者死亡原因分析及比较[J].肾脏病与透析肾移植杂志,2010,19(1):36-41.DOI:10.3969/j.issn.1006-298X.2010.01.007.
[13] 周健华.沙库巴曲/缬沙坦的研究进展[J].中国药师,2019,22(10):1902-1905.DOI:10.3969/j.issn.1008- 049X. 2019.10.034.
[14] Kuang H, Huang X, Zhou Z, et al. Sacubitril/valsartan in chronic kidney disease: from pharmacological mechanism to clinical application[J]. Eur J Pharmacol, 2021,907:174288. DOI: 10.1016/j.ejphar.2021.174288.
[15] Boerrigter G, Burnett JC. Recent advances in natriuretic peptides in congestive heart failure[J]. Expert Opin Investig Drugs, 2004,13(6):643-652. DOI: 10.1517/13543784.13.6.643.
[16] Patel P, Chen HH. Natriuretic peptides as a novel target in resistant hypertension[J]. Curr Hypertens Rep, 2015,17(3):18. DOI: 10.1007/s11906-014-0530-0.
[17] 楚艳贞,于林君,张彦昂.重组人脑利钠肽治疗心力衰竭的效果及对心功能、神经内分泌因子的影响[J].临床医学,2022,42(4):91-93.DOI:10.19528/j.issn.1003-3548. 2022.04.036.
[18] Singh JSS, Burrell LM, Cherif M, et al. Sacubitril/valsartan: beyond natriuretic peptides[J]. Heart, 2017,103(20):1569-1577. DOI: 10.1136/heartjnl-2017-311295.
[19] Vejakama P, Ingsathit A, McKay GJ, et al. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients[J]. BMC Nephrol, 2017,18(1):342. DOI: 10.1186/s12882-017-0753-9.
[20] Lee S, Oh J, Kim H, et al. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease[J]. ESC Heart Fail, 2020,7(3):1125-1129. DOI: 10.1002/ehf2.12659.
[21] Lihua W, Cheng L, Chen H, et al. Use of angiotensin receptor neprilysin inhibitor in patients on maintenance hemodialysis with reduced cardiac ejection fraction, real-world experience from a single center[J]. Iran J Kidney Dis, 2021,15(4):288-299.
[22] Fu S, Xu Z, Lin B, et al. Effects of sacubitril-valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis[J]. Front Med (Lausanne), 2021,8:657067. DOI: 10.3389/fmed.2021.657067.
[23] Wen Y, Xia Y, Gong Y. Effects and safety of Sacubitril/Valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients[J]. Am J Transl Res, 2022,14(5):3439-3447.
[24] Jing W, Vaziri ND, Nunes A, et al. LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD[J]. Am J Transl Res, 2017,9(12):5473-5484.
[25] Ushijima K, Ando H, Arakawa Y, et al. Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor[J]. Pharmacol Res Perspect, 2017,5(4):e00336. DOI: 10.1002/prp2.336.
[26] Suematsu Y, Jing W, Nunes A, et al. LCZ696 (Sacubitril/Valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease[J]. J Card Fail, 2018,24(4):266-275. DOI: 10.1016/j.cardfail.2017.12.010.
[27] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014,371(11):993-1004. DOI: 10.1056/NEJMoa1409077.
[28] Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction[J]. N Engl J Med, 2019,381(17):1609-1620. DOI: 10.1056/NEJMoa1908655.
[29] Zheng L, Xia B, Zhang X, et al. A Meta-analysis on the effect and safety of LCZ696 in the treatment of hypertension[J]. Cardiol Res Pract, 2021,2021:8867578. DOI: 10.1155/2021/8867578.
[30] Hersh LB, Rodgers DW. Neprilysin and amyloid beta peptide degradation[J]. Curr Alzheimer Res, 2008,5(2):225-231. DOI: 10.2174/156720508783954703.
[31] Campbell DJ. Long-term neprilysin inhibition - implications for ARNIs[J]. Nat Rev Cardiol, 2017,14(3):171-186. DOI: 10.1038/nrcardio.2016.200.